Premium
Infantile leukemia—What factors determine its distinct biological nature? Clinicopathological study of 78 cases
Author(s) -
Liu Xin,
Zhao Yue,
Luedke Catherine,
Jug Rachel,
Yang LianHe,
Lu Mark,
Pan Zenggang,
Wang Dehua,
Lorsbach Robert,
Shi Yang,
Knez Virginia,
Rehder Catherine,
Liang Xiayuan,
Wang Endi
Publication year - 2021
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13540
Subject(s) - leukemia , medicine , myeloid leukemia , overall survival , survival rate , myeloid , pediatrics , complete remission , lymphoblastic leukemia , oncology , chemotherapy
Infantile leukemia encompasses a heterogeneous group which needs stratifying for treatment selection. Methods We collected 78 cases of infantile leukemia and retrospectively analyzed their clinicopathological data. Results Infantile leukemia featured a ratio of acute myeloid leukemia (AML) to B‐lymphoblastic leukemia (B‐ALL) of 1:2, with a better survival for AML than B‐ALL (median survival 36 vs 24 months). When stratified by age, “early” infantile B‐ALL (2‐6 months) showed a high rate of KMT2A rearrangement (100%), similar to the rate seen in congenital B‐ALL (1 month) (100%) and higher than seen in “late” infantile B‐ALL (≥7 months) (68%). The three categories of infantile B‐ALL exhibited an age‐dependent increase in survival (median survival 8.5, 24, and >24 months, respectively). The age‐dependent survival benefit remained after excluding the cases negative for KMT2A rearrangement. Conversely, infantile AML lacked an age‐dependent pattern of survival. Conclusion The clinical outcome of infantile leukemia depends on the type of leukemia. Given the age‐dependent survival, infantile B‐ALL can be divided into three subcategories.